GGrantIndex
← Leaderboards

Shawn J. Skerrett

University Of Washington

$5,911,130
Attributed
$9,495,741
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,495,741 · 9

By mechanism

R01$7,184,230 · 3
R21$1,473,098 · 3
U54$748,029 · 2
R29$90,384 · 1

Top collaborators

Most similar at University Of Washington

Same institution · by research overlap

Others in their field

Top investigators on “Infection

Research focus

InfectionLungAlveolar MacrophagesPneumoniaPathogenExhibitsIn VivoMacrophageMorbidity - Disease RateLegionellosisNovel StrategiesResponseProductionHost DefenseAerosolizedLung InfectionsInflammatoryFrancisellaFrancisella TularensisCytokineCellsTularemiaImmune ResponseBacteria

Grant awards (25)

Combination host-directed and antibacterial therapy for pulmonary intracellular infections$760,910
R01 · FY2025 · AI
Combination host-directed and antibacterial therapy for pulmonary intracellular infections$738,160
R01 · FY2024 · AI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$633,062
R01 · FY2022 · AI
Global Gene Expression Responses of Francisella tularensis to intracellular Infection of Human Alveolar Macrophages$223,613
R21 · FY2022 · AI · contact PI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$583,781
R01 · FY2021 · AI
Global Gene Expression Responses of Francisella tularensis to intracellular Infection of Human Alveolar Macrophages$288,407
R21 · FY2021 · AI · contact PI
Genetically engineered macrophages to treat pulmonary infections$216,942
R21 · FY2021 · AI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$512,525
R01 · FY2020 · AI
Genetically engineered macrophages to treat pulmonary infections$276,097
R21 · FY2020 · AI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$493,087
R01 · FY2019 · AI
Human Alveolar Macrophage Interactions with Francisella tularensis$207,425
R21 · FY2019 · AI · contact PI
Engineered Antimicrobial Platform to Target Pulmonary Intracellular Infections$493,126
R01 · FY2018 · AI
Human Alveolar Macrophage Interactions with Francisella tularensis$260,614
R21 · FY2018 · AI · contact PI
Pulmonary Defenses Against Intracellular Infection$386,250
R01 · FY2016 · AI · contact PI
Pulmonary Defenses Against Intracellular Infection$386,250
R01 · FY2015 · AI · contact PI
Pulmonary Defenses Against Intracellular Infection$386,250
R01 · FY2014 · AI · contact PI
Pulmonary Defenses Against Intracellular Infection$363,075
R01 · FY2013 · AI · contact PI
Pulmonary Defenses Against Intracellular Infection$386,146
R01 · FY2012 · AI · contact PI
Pulmonary Infection & Inflammation$394,112
U54 · FY2008 · AI · contact PI
Airway Inflammation$353,917
U54 · FY2008 · AI · contact PI
Host Defense Against Intracellular Infection of the Lung$265,300
R01 · FY2005 · HL
Host Defense Against Intracellular Infection of the Lung$265,300
R01 · FY2004 · HL
Host Defense Against Intracellular Infection of the Lung$265,300
R01 · FY2003 · HL
Host Defense Against Intracellular Infection of the Lung$265,708
R01 · FY2002 · HL
HOST DEFENSE AGAINST INTRACELLULAR INFECTION OF THE LUNG$90,384
R29 · FY2000 · HL